Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis. [PDF]
Front Endocrinol (Lausanne)Zheng H, Han J.
europepmc +1 more source
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception. [PDF]
Cardiovasc DiabetolKoca N +5 more
europepmc +1 more source
Pioglitazone protects against trimethyltin hippocampal injury by reducing pyroptosis, mitochondrial dysregulation and ER stress. [PDF]
Sci RepAbaspour N +3 more
europepmc +1 more source
Pioglitazone mitigates early brain injury by suppressing neuroinflammation and oxidative stress after subarachnoid hemorrhage: a rodent model study. [PDF]
Ann MedCetinkaya K +8 more
europepmc +1 more source
Targeting the PPAR-γ-ABC transporter axis ameliorates secondary pulmonary alveolar proteinosis induced by indium oxide nanoparticles. [PDF]
Part Fibre ToxicolJeon S, Kim G, Cho WS.
europepmc +1 more source
Selective Pharmacological Activation of PPARα/δ/γ Alters the Triglyceride Composition of Fatty Liver in a Diet-Induced MASLD Mouse Model. [PDF]
BiomoleculesHishiki T +11 more
europepmc +1 more source
Pharmacological Targeting of Peroxisome Proliferator-activated Receptors for Prevention of Radiation-induced Cognitive Decline. [PDF]
Ann NeurosciGhanekar S +7 more
europepmc +1 more source
Effect of Locally-Administered Pioglitazone on the Survival of Dermal Skin Flaps in an Experimental Study on Rats. [PDF]
CureusBasagiannis ED +5 more
europepmc +1 more source
Correction to "Pioglitazone Effect on Glioma Stem Cell Lines: Really a Promising Drug Therapy for Glioblastoma?" [PDF]
PPAR Reseuropepmc +1 more source
Tracking of Neuroinflammation Dynamics During Combined Anti-β-Amyloid Therapy (AAT) and Immunomodulation in a Preclinical Alzheimer's Disease Model. [PDF]
Int J Mol SciWind-Mark K +13 more
europepmc +1 more source